Top

Published in:

01-03-2022 | Glioblastoma | Review

Contemporary RNA Therapeutics for Glioblastoma

Authors: Kaitlyn Melnick, Farhad Dastmalchi, Duane Mitchell, Maryam Rahman, Elias J. Sayour

Published in: NeuroMolecular Medicine | Issue 1/2022

Abstract

Glioblastoma (GBM) is the most common primary brain tumor in adults and is universally lethal with a median survival of less than two years with standard therapy. RNA-based immunotherapies have significant potential to establish a durable treatment response for malignant brain tumors including GBM. RNA offers clear advantages over antigen-focused approaches but cannot often be directly administered due to biological instability. This review will focus on utilization of RNA dendritic cell vaccines and RNA nanoparticle therapies in the treatment of GBM. RNA-pulsed dendritic cell vaccines have been shown to be safe in a small phase I clinical trial and RNA-loaded nanoparticle vaccines will soon be underway in GBM patients (NCT04573140).

Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., et al. (2020). Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. New England Journal of Medicine, 383(25), 2427–2438. https://doi.org/10.1056/NEJMoa2028436CrossRef

Bonehill, A., Heirman, C., Tuyaerts, S., Michiels, A., Breckpot, K., Brasseur, F., et al. (2004). Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. The Journal of Immunology, 172(11), 6649–6657.CrossRef

Chongsathidkiet, P., Jackson, C., Koyama, S., Loebel, F., Cui, X., Farber, S. H., et al. (2018). Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nature Medicine, 24(9), 1459–1468. https://doi.org/10.1038/s41591-018-0135-2CrossRefPubMedPubMedCentral

Ding, L., Li, J., Wu, C., Yan, F., Li, X., & Zhang, S. (2020). A self-assembled RNA-triple helix hydrogel drug delivery system targeting triple-negative breast cancer. Journal of Materials Chemistry B, 8(16), 3527–3533.CrossRef

Dunn-Pirio, A., Peters, K., DesJardins, A., Randazzo, D., Friedman, H., Healy, P., et al. (2017). Tumor stem cell RNA-loaded dendritic cell vaccine for recurrent glioblastoma: A phase 1 trial (S41. 004). AAN Enterprises.

Grippin, A. J., Wummer, B., Wildes, T., Dyson, K., Trivedi, V., Yang, C., et al. (2019). Dendritic cell-activating magnetic nanoparticles enable early prediction of antitumor response with magnetic resonance imaging. ACS Nano, 13(12), 13884–13898.CrossRef

Insug, O., Ku, G., Ertl, H., & Blaszczyk-Thurin, M. (2002). A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Research, 22(2A), 613–621.PubMed

Jin, J., Bae, K. H., Yang, H., Lee, S. J., Kim, H., Kim, Y., et al. (2011). In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjugate Chemistry, 22(12), 2568–2572.CrossRef

Kobayashi, T., Yamanaka, R., Homma, J., Tsuchiya, N., Yajima, N., Yoshida, S., et al. (2003). Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma. Cancer Immunology Immunotherapy, 52(10), 632–637.CrossRef

Learn, C. A., Fecci, P. E., Schmittling, R. J., Xie, W., Karikari, I., Mitchell, D. A., et al. (2006). Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clinical Cancer Research, 12(24), 7306–7315. https://doi.org/10.1158/1078-0432.CCR-06-1727CrossRefPubMed

Mitchell, D. A., Batich, K. A., Gunn, M. D., Huang, M.-N., Sanchez-Perez, L., Nair, S. K., et al. (2015a). Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature, 519(7543), 366–369.CrossRef

Mitchell, D. A., Sayour, E. J., Reap, E., Schmittling, R., DeLeon, G., Norberg, P., et al. (2015b). Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide. Cancer Immunology Research, 3(4), 320–325.CrossRef

Mitchell, D. A., Xie, W., Schmittling, R., Learn, C., Friedman, A., McLendon, R. E., et al. (2008). Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncology, 10(1), 10–18.CrossRef

Rahman, M., Ghiaseddin, A., Yegorov, O., Yang, C., Dechkovskaia, A., Tran, D., et al. (2019). ATIM-15. Sustained complete radiographic response and prolonged systemic immune activation in a patient with MGMT unmethylated midline glioblastoma receiving CMV pp65-LAMP RNA-pulsed dendritic cell vaccines. Neuro-oncology, 21, vi4.CrossRef

Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., et al. (2020). COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature, 586(7830), 594–599. https://doi.org/10.1038/s41586-020-2814-7CrossRefPubMed

Sayour, E. J., De Leon, G., Pham, C., Grippin, A., Kemeny, H., Chua, J., et al. (2016). Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles. Oncoimmunology. https://doi.org/10.1080/2162402X.2016.1256527CrossRefPubMedPubMedCentral

Sayour, E. J., Grippin, A., De Leon, G., Stover, B., Rahman, M., Karachi, A., et al. (2018). Personalized tumor RNA loaded lipid-nanoparticles prime the systemic and intratumoral milieu for response to cancer immunotherapy. Nano Letters. https://doi.org/10.1021/acs.nanolett.8b02179CrossRefPubMedPubMedCentral

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987–996. https://doi.org/10.1056/NEJMoa043330CrossRef

Yaghi, N. K., Wei, J., Hashimoto, Y., Kong, L.-Y., Gabrusiewicz, K., Nduom, E. K., et al. (2017). Immune modulatory nanoparticle therapeutics for intracerebral glioma. Neuro-Oncology, 19(3), 372–382.PubMed

Zhang, F., Parayath, N., Ene, C., Stephan, S., Koehne, A., Coon, M., et al. (2019). Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nature Communications, 10(1), 1–16.CrossRef

Title: Contemporary RNA Therapeutics for Glioblastoma
Authors: Kaitlyn Melnick
Farhad Dastmalchi
Duane Mitchell
Maryam Rahman
Elias J. Sayour
Publication date: 01-03-2022
Publisher: Springer US
Keywords: Glioblastoma
Glioblastoma
Brain Tumor
Glioblastoma
Published in: NeuroMolecular Medicine / Issue 1/2022
Print ISSN: 1535-1084
Electronic ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-021-08669-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Contemporary RNA Therapeutics for Glioblastoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Targeting Mitochondrial Oxidative Phosphorylation in Glioblastoma Therapy

Emerging Epigenetic Therapies for Brain Tumors

Sex Differences in Glioblastoma Immunotherapy Response

Emerging Frontiers of Therapeutic Strategies for Brain Tumors: A NeuroMolecular Medicine Special Issue

Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma

Stem-Like Cell Populations, p53-Pathway Activation and Mechanisms of Recurrence in Sonic Hedgehog Medulloblastoma